Precision’s early HBV gene editing data are mixed as biotech lays off staff...
Precision BioSciences reported that one of three patients with chronic hepatitis B who received the lowest dose of its experimental gene editing therapy saw a lasting drop in a measure of ...
View ArticleBridgeBio's Attruby sales underwhelm Wall Street despite growth
BridgeBio's sales of its new transthyretin amyloid cardiomyopathy drug almost doubled this quarter. But that still wasn't good enough for investors in what is becoming one of biotech's most competitive...
View ArticleNovavax expects Phase 4 Covid trial to cost up to $90M
Novavax says conducting a post-marketing study for its Covid-19 vaccine will cost between $70 million and $90 million, following the FDA's more stringent approval framework that strongly advised the...
View ArticleOpenAI-backed biotech Chai Discovery raises $70M Series A
Chai Discovery has closed a $70 million Series A round, attracting investment from some of the biggest VC firms in Silicon Valley to back one of the newest AI-focused startups in biotech. Founded in...
View ArticleNovo Nordisk, Sanofi, Lilly to face renewed fight over alleged 340B price fixing
A federal appeals court revived a case alleging that Novo Nordisk, Sanofi, Eli Lilly and AstraZeneca conspired to restrict 340B discounts to contract pharmacies. A panel of Second Circuit judges
View ArticleFDA approves targeted brain cancer drug from Jazz’s Chimerix buyout
The FDA on Wednesday granted accelerated approval to Jazz Pharmaceuticals’ targeted glioma drug dordaviprone, marking the first treatment specifically for patients with a common subtype of the rare...
View ArticleSixth Circuit judges uphold IRA decision in government’s favor
The federal government beat another legal challenge to Medicare drug price negotiations after an appeals court held that regional chambers of commerce lacked standing to bring the lawsuit. The decision...
View ArticleElevidys sales fall again in Sarepta's second quarter amid safety issues
Sarepta Therapeutics reported a second consecutive quarter of declining revenue from its Duchenne gene therapy Elevidys, following the death of two patients earlier this year. Second-quarter sales of...
View ArticleIovance trims workforce after cell therapy sales missed expectations
Iovance has downsized its workforce, a spokesperson confirmed to Endpoints News. The reduction affected less than 20% of the workforce, including both full-time employees and contractors at the...
View ArticleEli Lilly’s obesity pill is less effective than Novo Nordisk’s, pivotal data...
Eli Lilly’s GLP-1 pill allowed obese patients to lose up to 11.2% of their body weight after 72 weeks of treatment, the company said Thursday. This is lower than the benchmark ...
View ArticleMerck KGaA joins other drugmakers in considering direct-to-patient US sales
Add Merck KGaA to the list of pharma companies that are looking into direct-to-patient sales in the US as a strategy to address President Donald Trump’s “most favored nation” policy. “We have not yet...
View ArticleEndpoints livestream: What we learned from Q2 earnings about China, tariffs...
Today on Post-Hoc Live, we dug into second-quarter earnings, and how biotech and pharma companies are thinking about changes at the FDA, tariffs and "most-favored nation" policies from the Trump...
View ArticleLilly's rise in revenue clouded by Phase 3 obesity pill readout
Eli Lilly, the world’s most valuable pharma company, reeled in $15.56 billion in revenue in the second quarter of 2025, but the sales beat was overshadowed by lackluster data from a ...
View ArticleFDA removes hold on Valneva’s chikungunya vaccine in those over 60, adjusts...
Valneva said the FDA has lifted a pause on the use of its chikungunya vaccine Ixchiq in older adults and also updated the product’s prescribing information. The agency no longer advises holding off on...
View ArticleTranslucent raises $7M for AI to analyze financial performance
Translucent, a startup that uses AI to help healthcare organizations better understand their finances, has raised $7 million in seed funding, Endpoints News learned exclusively. Founded in 2024,...
View ArticleMerck’s infant RSV antibody gets CDC's recommendation
The CDC now recommends the use of Merck’s recently-approved RSV antibody in infants, after advisors to the agency voted in favor of the product in June. CDC Director Susan Monarez adopted the...
View ArticleScholar Rock expects September PDUFA for spinal muscular atrophy drug to stay...
Scholar Rock is not anticipating any delays to the PDUFA date for its lead asset apitegromab in spinal muscular atrophy, despite issues found at two third-party CDMO sites, with one of these run by...
View ArticleChinese biotech Minghui raises $131M to advance its PD-1xVEGF bispecific
A Chinese biotech developing a PD-1xVEGF bispecific and other antibody-drug conjugates has secured a nine-figure raise from blue-chip investors. Shanghai-based Minghui Pharmaceutical raised $131...
View ArticleXtalPi inks pact with Greg Verdine’s DoveTree; Regenxbio, AbbVie update deal
Plus, news about Assembly Biosciences, Vaxcyte, CorMedix, Melinta Therapeutics, Innogen, Sana Biotechnology, SNIPR Biome, Voyager Therapeutics, Gilead, Arcus, Travere and Alltrna: XtalPi to work with...
View Article